Alto Neuroscience Inc
ANRO3.600USD
-0.510-12.41%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
97.46MMarket Cap
LossP/E TTM
More Details of Alto Neuroscience Inc Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
Company Info
Ticker SymbolANRO
Company nameAlto Neuroscience Inc
IPO dateFeb 02, 2024
CEODr. Amit Etkin, M.D., Ph.D.
Number of employees76
Security typeOrdinary Share
Fiscal year-endFeb 02
Address650 Castro Street, Suite 450
CityMOUNTAIN VIEW
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code94041
Phone17732555012
Websitehttps://www.altoneuroscience.com/
Ticker SymbolANRO
IPO dateFeb 02, 2024
CEODr. Amit Etkin, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Ms. Gwill York
Ms. Gwill York
Independent Director
Independent Director
--
--
Mr. Nicholas (Nick) Smith
Mr. Nicholas (Nick) Smith
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Hanley
Mr. Michael Hanley
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Other
66.65%
Shareholders
Shareholders
Proportion
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Other
66.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
19.52%
Hedge Fund
14.77%
Venture Capital
13.80%
Investment Advisor
13.64%
Individual Investor
7.48%
Research Firm
1.06%
Private Equity
0.92%
Family Office
0.24%
Endowment Fund
0.08%
Other
28.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
175
22.95M
84.78%
-8.18M
2025Q1
171
24.58M
90.79%
-9.93M
2024Q4
154
26.22M
97.22%
-2.96M
2024Q3
131
26.77M
99.31%
+3.33M
2024Q2
102
22.89M
85.38%
+1.53M
2024Q1
71
21.11M
78.78%
+8.14M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Wave Global, LP
3.71M
13.7%
--
--
Mar 31, 2025
Armistice Capital LLC
1.60M
5.91%
+950.00K
+146.15%
Mar 31, 2025
Point72 Asset Management, L.P.
1.24M
4.58%
-452.10K
-26.72%
Mar 31, 2025
Etkin (Amit)
1.21M
4.45%
--
--
Mar 17, 2025
Franklin Advisers, Inc.
1.16M
4.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.22M
4.5%
-11.02K
-0.90%
Mar 31, 2025
Vestal Point Capital, LP
915.00K
3.38%
--
--
Mar 31, 2025
Marshall Wace LLP
852.99K
3.15%
+15.62K
+1.86%
Mar 31, 2025
Cox (Christopher Nixon)
715.65K
2.64%
--
--
Mar 17, 2025
72 Investment Holdings, LLC
667.78K
2.47%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
